Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

bioMérieux S.A.. (1/19/17). "Press Release: bioMérieux – Fourth-Quarter 2016 Business Review". Marcy l’Étoile.

Organisations Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
  Organisation 2 bioTheranostics Inc.
Products Product in vitro diagnostics (IVD)
  Product 2 FilmArray® PCR test (product series)
Person Person Mérieux, Alexandre (bioMérieux 201404– CEO before VP Industrial Microbiology)
     


> Remarkable growth in sales in 2016, up 9.6% like-for-like, lifted by all regions and all strategic lines:
€2,103 million in sales
Up 7.1% as reported

> Strong contribution from the Americas region to Group sales growth

> Success for FilmArray® in molecular biology, with sales at almost €250 million for full-year 2016

> bioMérieux expects contributive operating income before non-recurring items to be slightly above its previous target, moving closer to €300 million


Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux's excellent sales dynamic helped drive organic sales growth of 9.6% and confirms the relevance of our positioning as a specialist in infectious diseases. Given the firm fourth-quarter performance, contributive operating income before non-recurring items should come in slightly higher than our previous estimate. In this favorable environment, the Company will continue to pursue its strategic investments in order to innovate and provide its customers with high value-added medical solutions, making a lasting contribution to improved patient care."

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the twelve months ended December 31, 2016.


SALES

Consolidated sales amounted to €2,103 million in 2016, versus €1,965 million in 2015. Year-on-year organic sales growth (i.e., at constant exchange rates and scope of consolidation) outperformed objectives at 9.6%, led by an acceleration of around 500bp driven by FilmArray® sales. In a volatile currency environment, reported sales growth came to 7.1%, held back by a negative currency effect of around €33 million, as well as the change in scope resulting primarily from the deconsolidation of bioTheranostics as of January 1, 2016.

Download [ www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_sales_q4_2016.pdf ]


   
Record changed: 2017-02-09

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Mérieux (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px